31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2021)

Virtual 09 July 2021 - 12 July 2021

Adding azithromycin to standard care yields no survival benefit in ambulatory managed COVID-19

24 Aug 2021 by

The addition of azithromycin to standard care did not reduce hospitalization or mortality risk in patients with mild-to-moderate COVID-19 who underwent ambulatory management, according to results of the ATOMIC2 trial presented at ECCMID 2021.

Adding azithromycin to standard care yields no survival benefit in ambulatory managed COVID-19

24 Aug 2021

CoronaVac: Does it work against the Gamma variant?

03 Aug 2021 by

The CoronaVac vaccine shows significantly reduced neutralizing activity against the Gamma variant (previously known as P.1) of SARS-CoV-2 — indicating that the variant may be able to escape immune response in fully vaccinated people as well as reinfect those who had recovered from COVID-19, according to an immunological study presented at ECCMID 2021.

CoronaVac: Does it work against the Gamma variant?

03 Aug 2021

Antigen rapid tests: The new COVID-19 strategy moving forward?

31 Jul 2021 by

Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.

Antigen rapid tests: The new COVID-19 strategy moving forward?

31 Jul 2021

Combined Ag/Ab rapid testing boosts case-finding in COVID-19

29 Jul 2021 by

A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.

Combined Ag/Ab rapid testing boosts case-finding in COVID-19

29 Jul 2021

Antigen rapid test vs RT-PCR for COVID-19: What you need to know

29 Jul 2021 by

While RT-PCR is the current gold standard to confirm a SARS-CoV-2 infection, antigen rapid test (ART) for COVID-19 allows for quick detection of SARS-CoV-2 and thus fast triaging of infected patients requiring isolation at the population level, according to studies presented at ECCMID 2021.

Antigen rapid test vs RT-PCR for COVID-19: What you need to know

29 Jul 2021

First dose of ChAdOx1, BNT162b2 vaccines may be protective in LTCF residents after 4 weeks

26 Jul 2021 by

Long-term care facility (LTCF) residents aged ≥65 years appeared to be protected from COVID-19 4–7 weeks after receiving their first dose of the ChAdOx1 nCoV-19 or BNT162b2 vaccine, according to a study presented at ECCMID 2021.

First dose of ChAdOx1, BNT162b2 vaccines may be protective in LTCF residents after 4 weeks

26 Jul 2021

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

26 Jul 2021 by

Patients with psoriasis taking the immunosuppressant methotrexate had low antibody responses to SARS-CoV-2 after receiving the first dose of Pfizer-BioNTech’s BNT162b2 vaccine but had shown T-cell responses, according to a study that was the first to look at T-cell responses in patients taking methotrexate.

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

26 Jul 2021

Real-world data back remdesivir benefit for hospitalized COVID-19 patients

23 Jul 2021 by

Findings from real-world studies presented at ECCMID 2021 showed improved survival outcomes with remdesivir in hospitalized COVID-19 patients.

Real-world data back remdesivir benefit for hospitalized COVID-19 patients

23 Jul 2021

Casirivimab/imdevimab tied to better outcomes than bamlanivimab/etesevimab in COVID-19 outpatients infected by Gamma variant

23 Jul 2021 by

Treatment with casirivimab/imdevimab combination therapy appears to be associated with a reduced risk of hospitalization or death compared with bamlanivimab/etesevimab in outpatients with COVID-19 infected by the Gamma variant, according to a study presented at ECCMID 2021.

Casirivimab/imdevimab tied to better outcomes than bamlanivimab/etesevimab in COVID-19 outpatients infected by Gamma variant

23 Jul 2021

Regdanvimab shows potential for mild-to-moderate COVID-19

21 Jul 2021 by

The monoclonal antibody regdanvimab showed promise in the treatment of patients with mild-to-moderate* COVID-19, a pivotal phase II/III trial has shown.

Regdanvimab shows potential for mild-to-moderate COVID-19

21 Jul 2021